Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma
- Conditions
- Plasma Cell Leukemia in RemissionPlasma Cell Myeloma
- Interventions
- Procedure: Autologous Hematopoietic Stem Cell TransplantationDrug: CyclophosphamideBiological: FilgrastimOther: Laboratory Biomarker AnalysisDrug: LenalidomideProcedure: pheresisDrug: MelphalanBiological: PaliferminRadiation: Total Marrow Irradiation
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2017-12-13
- Lead Sponsor
- City of Hope Medical Center
- Registration Number
- NCT03100877
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- Conditions
- Metastatic Thyroid Cancer
- Interventions
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 19
- Registration Number
- NCT03099356
- Locations
- 🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
- Conditions
- Acute LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeLangerhans Cell HistiocytosisAcute Biphenotypic LeukemiaAcute Lymphoblastic LeukemiaChronic Myelomonocytic LeukemiaNon-Hodgkin LymphomaRecurrent Hodgkin LymphomaTherapy-Related Myelodysplastic SyndromeAcute Myeloid Leukemia
- Interventions
- Biological: Anti-Thymocyte GlobulinDrug: BusulfanDrug: ClofarabineDrug: CyclophosphamideBiological: Filgrastim-sndzDrug: FludarabineDrug: MelphalanDrug: Mycophenolate MofetilBiological: RituximabDrug: TacrolimusRadiation: Total-Body IrradiationProcedure: Umbilical Cord Blood Transplantation
- First Posted Date
- 2017-03-30
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT03096782
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2017-03-28
- Last Posted Date
- 2019-02-27
- Lead Sponsor
- The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
- Target Recruit Count
- 10
- Registration Number
- NCT03093168
- Locations
- 🇨🇳
Henan Province of TCM, Zhengzhou, Henan, China
CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2017-03-24
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 23
- Registration Number
- NCT03089203
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Cyclophosphamide vs. Infliximab for Refractory Idiopathic Scleritis (CIRIS)
- Conditions
- Idiopathic Refractory Scleritis
- Interventions
- First Posted Date
- 2017-03-23
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Hospices Civils de Lyon
- Registration Number
- NCT03088293
Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide
- Conditions
- Acute Lymphocytic LeukemiaNon-hodgkin LymphomaChronic Lymphocytic LeukemiaAcute Myeloid LeukemiaMyelodysplastic Syndrome
- Interventions
- Drug: CyclophosphamideDrug: TacrolimusDrug: Mycophenolate mofetilOther: Haploidentical Stem Cell Transplantation
- First Posted Date
- 2017-03-23
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Loyola University
- Target Recruit Count
- 5
- Registration Number
- NCT03088709
- Locations
- 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
- Conditions
- Solid Tumor
- Interventions
- First Posted Date
- 2017-03-21
- Last Posted Date
- 2022-09-23
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 70
- Registration Number
- NCT03085914
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Mayo Clinic Arizona, Phoenix, Arizona, United States
Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC)
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Biological: Retroviral vector-transduced autologous T cells to express anti-GPC3 CARsDrug: FludarabineDrug: Cyclophosphamide
- First Posted Date
- 2017-03-20
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- Xinqiao Hospital of Chongqing
- Target Recruit Count
- 20
- Registration Number
- NCT03084380
- Locations
- 🇨🇳
Department of Oncology, Xinqiao Hospital, ChongQing, Chongqing, China
Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease
- Conditions
- Sickle Cell Disease
- Interventions
- Procedure: haploidentical stem cell transplantDrug: FilgrastimDrug: SirolimusDrug: AlemtuzumabDrug: PentostatinDrug: CyclophosphamideDrug: Hydroxyurea
- First Posted Date
- 2017-03-13
- Last Posted Date
- 2024-08-07
- Target Recruit Count
- 57
- Registration Number
- NCT03077542
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.